Ribociclib forestalls recurrence also in early breast cancer

New results come from an interim analysis of a phase 3 randomized trial comparing maintenance therapy with ribociclib plus endocrine therapy with an aromatase inhibitor to endocrine therapy alone.

Read the full article here

Related Articles